263 related articles for article (PubMed ID: 33013907)
1. Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells.
Cooke RE; Quinn KM; Quach H; Harrison S; Prince HM; Koldej R; Ritchie D
Front Immunol; 2020; 11():2153. PubMed ID: 33013907
[TBL] [Abstract][Full Text] [Related]
2. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
[TBL] [Abstract][Full Text] [Related]
3. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor.
Condomines M; Quittet P; Lu ZY; Nadal L; Latry P; Lopez E; Baudard M; Requirand G; Duperray C; Schved JF; Rossi JF; Tarte K; Klein B
J Immunol; 2006 Jun; 176(11):6631-9. PubMed ID: 16709821
[TBL] [Abstract][Full Text] [Related]
4. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
Front Immunol; 2021; 12():618610. PubMed ID: 33717112
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
6. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
Front Immunol; 2019; 10():334. PubMed ID: 30894856
[TBL] [Abstract][Full Text] [Related]
7. Highly proliferative and functional PD-1
Batorov EV; Aristova TA; Pronkina NV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Shevela EY; Ostanin AA; Chernykh ER
Int Immunopharmacol; 2021 Nov; 100():108093. PubMed ID: 34474273
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.
Arteche-López A; Kreutzman A; Alegre A; Sanz Martín P; Aguado B; González-Pardo M; Espiño M; Villar LM; García Belmonte D; de la Cámara R; Muñoz-Calleja C
Bone Marrow Transplant; 2017 Jun; 52(6):832-838. PubMed ID: 28368375
[TBL] [Abstract][Full Text] [Related]
9. CD4
Batorov EV; Tikhonova MA; Kryuchkova IV; Sergeevicheva VV; Sizikova SA; Ushakova GY; Batorova DS; Gilevich AV; Ostanin AA; Shevela EY; Chernykh ER
Int J Hematol; 2017 Jul; 106(1):108-115. PubMed ID: 28293817
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
[TBL] [Abstract][Full Text] [Related]
11. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
12. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation.
Servais S; Lengline E; Porcher R; Carmagnat M; Peffault de Latour R; Robin M; Sicre de Fontebrune F; Clave E; Maki G; Granier C; Xhaard A; Dhedin N; Molina JM; Toubert A; Moins-Teisserenc H; Socie G
Biol Blood Marrow Transplant; 2014 Apr; 20(4):507-17. PubMed ID: 24406505
[TBL] [Abstract][Full Text] [Related]
13. CD4 T Cell Help via B Cells Is Required for Lymphopenia-Induced CD8 T Cell Proliferation.
Ayasoufi K; Fan R; Fairchild RL; Valujskikh A
J Immunol; 2016 Apr; 196(7):3180-90. PubMed ID: 26912319
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
Svane IM; Nikolajsen K; Johnsen HE
Scand J Immunol; 2007 Oct; 66(4):465-75. PubMed ID: 17850592
[TBL] [Abstract][Full Text] [Related]
15. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants.
Rutella S; Rumi C; Laurenti L; Pierelli L; Sora' F; Sica S; Leone G
Br J Haematol; 2000 Jan; 108(1):105-15. PubMed ID: 10651733
[TBL] [Abstract][Full Text] [Related]
16. CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation.
Heck C; Steiner S; Kaebisch EM; Frentsch M; Wittenbecher F; Scheibenbogen C; Hanitsch LG; Nogai A; le Coutre P; Bullinger L; Blau IW; Na IK
Front Immunol; 2021; 12():736137. PubMed ID: 34659226
[TBL] [Abstract][Full Text] [Related]
17. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.
Nunes C; Wong R; Mason M; Fegan C; Man S; Pepper C
Clin Cancer Res; 2012 Feb; 18(3):678-87. PubMed ID: 22190592
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
19. Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response.
Bandera A; Trabattoni D; Pacei M; Fasano F; Suardi E; Cesari M; Marchetti G; Pogliani EM; Franzetti F; Clerici M; Gori A
PLoS One; 2008; 3(10):e3616. PubMed ID: 18974880
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
